World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
31070
World Ranking
13076
National Ranking
6677

Overview

Philip A. Philip is affiliated with Wayne State University in the United States and has a research focus spanning medicine and biochemistry, genetics, and molecular biology. Their academic contributions are primarily concentrated in oncology, with significant work also in molecular biology, cancer research, pulmonary and respiratory medicine, and surgery.

Their research topics cover a range of areas within oncology and cancer biology. These include pancreatic and hepatic oncology research, cancer genomics and diagnostics, colorectal cancer treatments and studies, genetic factors in colorectal cancer, neuroendocrine tumor research advances, gastric cancer management and outcomes, and cholangiocarcinoma and gallbladder cancer studies.

Philip A. Philip has published extensively in several prominent scientific journals. Frequent venues for their work include the Journal of Clinical Oncology, Cancer Research, Cancer and Metastasis Reviews, Clinical Cancer Research, and Cancers.

Notable recent papers authored by Philip A. Philip include:

  • Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study (2021), published in The Lancet. Gastroenterology & Hepatology
  • Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406) (2020), published in Journal of Clinical Oncology
  • Neoadjuvant therapy for pancreatic cancer (2023), published in Nature Reviews Clinical Oncology
  • Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma (2021), published in JAMA Oncology
  • Metastatic Pancreatic Cancer: ASCO Guideline Update (2020), published in Journal of Clinical Oncology

Frequent collaborators in their research include:

  • Anthony F. Shields
  • Asfar S. Azmi
  • Mohammed Najeeb Al Hallak
  • Md. Hafiz Uddin
  • Amro Aboukameel

Best Publications

  • Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

    Charles S. Fuchs;Toshihiko Doi;Raymond W. Jang;Raymond W. Jang;Kei Muro

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells

    Yiwei Li;Timothy G. VandenBoom;Dejuan Kong;Zhiwei Wang

  • Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

    Philip A. Philip;Jacqueline Benedetti;Christopher L. Corless;Ralph Wong

  • Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

    Philip J. Johnson;Shukui Qin;Joong Won Park;Ronnie T.P. Poon

  • Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

    Milind Javle;Maeve Lowery;Rachna T. Shroff;Karl Heinz Weiss

  • Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer

    Philip A. Philip;Michelle R. Mahoney;Cristine Allmer;James Thomas

  • Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.

    Shadan Ali;Aamir Ahmad;Sanjeev Banerjee;Subhash Padhye

  • miR-146a suppresses invasion of pancreatic cancer cells

    Yiwei Li;Timothy G. VandenBoom;Zhiwei Wang;Dejuan Kong

  • Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

    Eileen M. O'Reilly;Do Youn Oh;Neesha Dhani;Daniel J. Renouf

  • Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.

    Matthew H.G. Katz;Qian Shi;Syed A. Ahmad;Joseph M. Herman

  • Inactivation of Nuclear Factor κB by Soy Isoflavone Genistein Contributes to Increased Apoptosis Induced by Chemotherapeutic Agents in Human Cancer Cells

    Yiwei Li;Fakhara Ahmed;Shadan Ali;Philip A. Philip

  • Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

    Scott Kopetz;Katherine A. Guthrie;Van K. Morris;Heinz Josef Lenz

  • Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer

    Philip A. Philip;Michelle R. Mahoney;Cristine Allmer;James Thomas

  • Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Davendra P.S. Sohal;Pamela B. Mangu;Alok A. Khorana;Manish A. Shah

  • Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design

    Matthew Harold Katz;Robert Marsh;Joseph M. Herman;Qian Shi

  • Molecular Evidence for Increased Antitumor Activity of Gemcitabine by Genistein In vitro and In vivo Using an Orthotopic Model of Pancreatic Cancer

    Sanjeev Banerjee;Yuxiang Zhang;Shadan Ali;Mohammad Bhuiyan

  • Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

    Sam J. Lubner;Michelle R. Mahoney;Jill L. Kolesar;Noelle K. LoConte

  • Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

    Ramesh K. Ramanathan;Shannon L. McDonough;Philip A. Philip;Sunil R. Hingorani

  • Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

    Milind Javle;Sameek Roychowdhury;Robin Kate Kelley;Saeed Sadeghi

Frequent Co-Authors

Fazlul H. Sarkar
Fazlul H. Sarkar Wayne State University
Heinz-Josef Lenz
Heinz-Josef Lenz University of Southern California
Richard M. Goldberg
Richard M. Goldberg West Virginia University
Eileen M. O’Reilly
Eileen M. O’Reilly Memorial Sloan Kettering Cancer Center
Andrew M. Lowy
Andrew M. Lowy University of California, San Diego
Wafik S. El-Deiry
Wafik S. El-Deiry Brown University
Yiwei Li
Yiwei Li Wayne State University
Jordan Berlin
Jordan Berlin Vanderbilt University Medical Center
Sanjeev Banerjee
Sanjeev Banerjee Wayne State University
David Goldstein
David Goldstein University of New South Wales

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in medical careers beyond the traditional M.D. route? Online health degrees offer flexible options for both entry-level and advanced learners. For nurses looking to advance, dnp online programs cheap make it possible to earn a Doctor of Nursing Practice while saving on tuition and managing work commitments.

Pharmacists are also in high demand, and pursuing an online pharmacy degree can be a cost-effective path to entering this respected field. Those interested in the fast-growing field of health data can explore a him degree online for roles in managing digital health records and information systems.

For students looking for a quick entry point into healthcare, medical billing and coding is a smart choice. Learning about the average cost of medical billing and coding program can help you plan your education and budget.

Each of these online pathways can prepare you for a rewarding healthcare career without stepping foot on campus.

Best Scientists Citing Philip A. Philip

Trending Scientists